Ownership and insider activity for Fulcrum Therapeutics, Inc. (FULC): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical firm committed to developing life-improving treatments for patients in the United States afflicted by genetically defined diseases with significant unmet medical needs.
Price
| Price | $3.79 |
| Market Cap | $289M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-17 | TANG KEVIN | P-Purchase | 50,945 | $179K |
| 2026-07-16 | TANG KEVIN | P-Purchase | 116,671 | $415K |
| 2026-07-15 | TANG KEVIN | P-Purchase | 107,377 | $382K |
| 2026-07-14 | TANG KEVIN | P-Purchase | 75,952 | $272K |
| 2026-07-14 | TANG KEVIN | P-Purchase | 53,651 | $191K |
| 2026-07-13 | TANG KEVIN | P-Purchase | 12,966 | $46K |
| 2026-07-13 | TANG KEVIN | |||
| 2026-06-30 | Banks Sonja | A-Award | 32,000 | $117K |
| 2026-06-30 | Dorton Katina | A-Award | 32,000 | $117K |
| 2026-06-30 | Gould Robert J | A-Award | 32,000 | $117K |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $407000 | $72.8M | $96.7M | $57.1M | $35.4M | $35.1M | $25.6M | $58.2M | $197.5M |
| Short-term Investments | 0 | 0 | 0 | $55.9M | $182.8M | $167.8M | $210.7M | $182.8M | $154.8M |
| Receivables | $39000 | $501000 | $111000 | $2.7M | $4.1M | $1.1M | $2.2M | $3.3M | $1.1M |
| Inventory | $734000 | $559000 | $3.0M | -$2.8M | -$473000 | 0 | 0 | 0 | 0 |
| Total Current Assets | $1.3M | $74.1M | $100.1M | $112.9M | $226.0M | $207.5M | $242.2M | $249.9M | $357.5M |
| Property, Plant & Equipment | $2.9M | $10.5M | $87.9M | $8.4M | $7.4M | $16.0M | $12.4M | $9.6M | $7.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $4.3M | $85.8M | $110.4M | $129.6M | $235.0M | $226.7M | $257.7M | $260.7M | $366.3M |
| Accounts Payable | $1.7M | $1.3M | $2.2M | $4.1M | $4.8M | $3.6M | $2.8M | $1.2M | $1.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | $2.6M | 0 | 0 | 0 |
| Total Current Liabilities | $2.8M | $4.2M | $12.1M | $26.7M | $19.2M | $16.7M | $13.7M | $11.0M | $13.0M |
| Long-term Debt | $34.6M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $4.0M |
| Total Liabilities | $3.0M | $9.8M | $23.3M | $34.4M | $23.5M | $27.7M | $22.5M | $17.7M | $17.3M |
| Retained Earnings | -$35.5M | -$68.1M | -$150.8M | -$221.6M | -$302.5M | -$412.3M | -$509.7M | -$519.4M | -$594.3M |
| Total Equity | $1.3M | $76.0M | $87.2M | $95.2M | $211.5M | $198.9M | $235.2M | $243.0M | $349.0M |
| Total Debt | $34.6M | $46000 | $50000 | $17000 | 0 | $13.4M | $10.8M | $8.6M | $6.4M |
| Net Debt | $34.2M | -$72.8M | -$96.7M | -$112.9M | -$218.2M | -$189.5M | -$225.4M | -$232.4M | -$345.9M |
| Working Capital | -$1.4M | $69.9M | $87.9M | $86.2M | $206.8M | $190.8M | $228.5M | $238.9M | $344.4M |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 31.35 |
| Piotroski F-Score | 2 |
| Altman Z-Score | 22.97 |
Profitability
| Return on Equity | -28.54% |
| Return on Invested Capital | -27.40% |
| Return on Assets | -26.24% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ADCT · BCYC · CMPX · LCTX · LXRX · NGNE · NMRA
Explore sector: Healthcare · Biotechnology
More sections of FULC: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks